NOVARTIS AG-SPONSORED ADR (NVS) Fundamental Analysis & Valuation
NYSE:NVS • US66987V1098
Current stock price
154.05 USD
-1.01 (-0.65%)
At close:
153.8 USD
-0.25 (-0.16%)
After Hours:
This NVS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. NVS Profitability Analysis
1.1 Basic Checks
- In the past year NVS was profitable.
- In the past year NVS had a positive cash flow from operations.
- Each year in the past 5 years NVS has been profitable.
- Each year in the past 5 years NVS had a positive operating cash flow.
1.2 Ratios
- Looking at the Return On Assets, with a value of 12.60%, NVS belongs to the top of the industry, outperforming 93.78% of the companies in the same industry.
- The Return On Equity of NVS (30.31%) is better than 94.30% of its industry peers.
- With an excellent Return On Invested Capital value of 19.32%, NVS belongs to the best of the industry, outperforming 95.34% of the companies in the same industry.
- Measured over the past 3 years, the Average Return On Invested Capital for NVS is above the industry average of 13.06%.
- The 3 year average ROIC (17.15%) for NVS is below the current ROIC(19.32%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.6% | ||
| ROE | 30.31% | ||
| ROIC | 19.32% |
ROA(3y)13.05%
ROA(5y)12.66%
ROE(3y)29.75%
ROE(5y)27.29%
ROIC(3y)17.15%
ROIC(5y)14%
1.3 Margins
- The Profit Margin of NVS (24.83%) is better than 92.75% of its industry peers.
- NVS's Profit Margin has improved in the last couple of years.
- The Operating Margin of NVS (33.18%) is better than 95.85% of its industry peers.
- In the last couple of years the Operating Margin of NVS has grown nicely.
- With an excellent Gross Margin value of 75.82%, NVS belongs to the best of the industry, outperforming 83.42% of the companies in the same industry.
- In the last couple of years the Gross Margin of NVS has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 33.18% | ||
| PM (TTM) | 24.83% | ||
| GM | 75.82% |
OM growth 3Y12.14%
OM growth 5Y6.09%
PM growth 3Y15.69%
PM growth 5Y8.94%
GM growth 3Y0.74%
GM growth 5Y1.28%
2. NVS Health Analysis
2.1 Basic Checks
- NVS has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
- NVS has less shares outstanding than it did 1 year ago.
- The number of shares outstanding for NVS has been reduced compared to 5 years ago.
- Compared to 1 year ago, NVS has a worse debt to assets ratio.
2.2 Solvency
- An Altman-Z score of 4.41 indicates that NVS is not in any danger for bankruptcy at the moment.
- NVS's Altman-Z score of 4.41 is fine compared to the rest of the industry. NVS outperforms 71.50% of its industry peers.
- The Debt to FCF ratio of NVS is 2.32, which is a good value as it means it would take NVS, 2.32 years of fcf income to pay off all of its debts.
- NVS has a Debt to FCF ratio of 2.32. This is amongst the best in the industry. NVS outperforms 93.78% of its industry peers.
- NVS has a Debt/Equity ratio of 0.64. This is a neutral value indicating NVS is somewhat dependend on debt financing.
- NVS has a Debt to Equity ratio of 0.64. This is in the lower half of the industry: NVS underperforms 69.43% of its industry peers.
- Even though the debt/equity ratio score it not favorable for NVS, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.64 | ||
| Debt/FCF | 2.32 | ||
| Altman-Z | 4.41 |
ROIC/WACC4.07
WACC4.75%
2.3 Liquidity
- A Current Ratio of 1.12 indicates that NVS should not have too much problems paying its short term obligations.
- NVS has a Current ratio of 1.12. This is amonst the worse of the industry: NVS underperforms 84.46% of its industry peers.
- NVS has a Quick Ratio of 1.12. This is a bad value and indicates that NVS is not financially healthy enough and could expect problems in meeting its short term obligations.
- NVS has a worse Quick ratio (0.89) than 82.38% of its industry peers.
- NVS does not score too well on the current and quick ratio evaluation. However, as it has excellent solvency and profitability, these ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.12 | ||
| Quick Ratio | 0.89 |
3. NVS Growth Analysis
3.1 Past
- The Earnings Per Share has grown by an nice 14.98% over the past year.
- Measured over the past years, NVS shows a quite strong growth in Earnings Per Share. The EPS has been growing by 9.21% on average per year.
- NVS shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 8.91%.
- Measured over the past years, NVS shows a small growth in Revenue. The Revenue has been growing by 2.45% on average per year.
EPS 1Y (TTM)14.98%
EPS 3Y13.63%
EPS 5Y9.21%
EPS Q2Q%2.53%
Revenue 1Y (TTM)8.91%
Revenue growth 3Y9.1%
Revenue growth 5Y2.45%
Sales Q2Q%1.39%
3.2 Future
- NVS is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.48% yearly.
- The Revenue is expected to grow by 4.99% on average over the next years.
EPS Next Y-0.14%
EPS Next 2Y4.63%
EPS Next 3Y6.15%
EPS Next 5Y7.48%
Revenue Next Year2.53%
Revenue Next 2Y3.82%
Revenue Next 3Y4.55%
Revenue Next 5Y4.99%
3.3 Evolution
- The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. NVS Valuation Analysis
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 17.06, the valuation of NVS can be described as rather expensive.
- Based on the Price/Earnings ratio, NVS is valued cheaper than 84.97% of the companies in the same industry.
- NVS is valuated rather cheaply when we compare the Price/Earnings ratio to 26.78, which is the current average of the S&P500 Index.
- NVS is valuated rather expensively with a Price/Forward Earnings ratio of 17.09.
- 81.35% of the companies in the same industry are more expensive than NVS, based on the Price/Forward Earnings ratio.
- NVS is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 23.54, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.06 | ||
| Fwd PE | 17.09 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, NVS is valued cheaper than 83.94% of the companies in the same industry.
- Based on the Price/Free Cash Flow ratio, NVS is valued cheaply inside the industry as 84.97% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 19.39 | ||
| EV/EBITDA | 13.29 |
4.3 Compensation for Growth
- The excellent profitability rating of NVS may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)1.85
EPS Next 2Y4.63%
EPS Next 3Y6.15%
5. NVS Dividend Analysis
5.1 Amount
- NVS has a Yearly Dividend Yield of 3.03%. Purely for dividend investing, there may be better candidates out there.
- NVS's Dividend Yield is rather good when compared to the industry average which is at 0.43. NVS pays more dividend than 94.82% of the companies in the same industry.
- Compared to an average S&P500 Dividend Yield of 1.83, NVS pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.03% |
5.2 History
- The dividend of NVS has a limited annual growth rate of 5.38%.
- NVS has been paying a dividend for at least 10 years, so it has a reliable track record.
- NVS has not decreased its dividend in the past 5 years, so it has a somewhat stable track record.
Dividend Growth(5Y)5.38%
Div Incr Years6
Div Non Decr Years6
5.3 Sustainability
- NVS pays out 55.91% of its income as dividend. This is a bit on the high side, but may be sustainable.
- NVS's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP55.91%
EPS Next 2Y4.63%
EPS Next 3Y6.15%
NVS Fundamentals: All Metrics, Ratios and Statistics
154.05
-1.01 (-0.65%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-04 2026-02-04/bmo
Earnings (Next)04-28 2026-04-28
Inst Owners43.85%
Inst Owner Change-3.31%
Ins Owners0.03%
Ins Owner ChangeN/A
Market Cap295.59B
Revenue(TTM)56.33B
Net Income(TTM)13.98B
Analysts70.59
Price Target161.32 (4.72%)
Short Float %0.44%
Short Ratio3.02
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.03% |
Yearly Dividend4.02
Dividend Growth(5Y)5.38%
DP55.91%
Div Incr Years6
Div Non Decr Years6
Ex-Date03-11 2026-03-11 (4.740247)
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-1.14%
Min EPS beat(2)-2.1%
Max EPS beat(2)-0.17%
EPS beat(4)2
Avg EPS beat(4)1.23%
Min EPS beat(4)-2.1%
Max EPS beat(4)6.59%
EPS beat(8)6
Avg EPS beat(8)2.93%
EPS beat(12)9
Avg EPS beat(12)2.91%
EPS beat(16)11
Avg EPS beat(16)2.66%
Revenue beat(2)0
Avg Revenue beat(2)-3.85%
Min Revenue beat(2)-4.89%
Max Revenue beat(2)-2.82%
Revenue beat(4)0
Avg Revenue beat(4)-2.92%
Min Revenue beat(4)-4.89%
Max Revenue beat(4)-1.13%
Revenue beat(8)2
Avg Revenue beat(8)-1.5%
Revenue beat(12)3
Avg Revenue beat(12)-2.67%
Revenue beat(16)4
Avg Revenue beat(16)-0.2%
PT rev (1m)3.41%
PT rev (3m)19.46%
EPS NQ rev (1m)0.95%
EPS NQ rev (3m)-7.42%
EPS NY rev (1m)-0.83%
EPS NY rev (3m)-4.45%
Revenue NQ rev (1m)0.03%
Revenue NQ rev (3m)-3.07%
Revenue NY rev (1m)-0.22%
Revenue NY rev (3m)-0.17%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.06 | ||
| Fwd PE | 17.09 | ||
| P/S | 5.25 | ||
| P/FCF | 19.39 | ||
| P/OCF | 15.44 | ||
| P/B | 6.41 | ||
| P/tB | N/A | ||
| EV/EBITDA | 13.29 |
EPS(TTM)9.03
EY5.86%
EPS(NY)9.02
Fwd EY5.85%
FCF(TTM)7.94
FCFY5.16%
OCF(TTM)9.98
OCFY6.48%
SpS29.36
BVpS24.04
TBVpS-4.61
PEG (NY)N/A
PEG (5Y)1.85
Graham Number69.89
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.6% | ||
| ROE | 30.31% | ||
| ROCE | 22.34% | ||
| ROIC | 19.32% | ||
| ROICexc | 22.42% | ||
| ROICexgc | 94.51% | ||
| OM | 33.18% | ||
| PM (TTM) | 24.83% | ||
| GM | 75.82% | ||
| FCFM | 27.06% |
ROA(3y)13.05%
ROA(5y)12.66%
ROE(3y)29.75%
ROE(5y)27.29%
ROIC(3y)17.15%
ROIC(5y)14%
ROICexc(3y)20.47%
ROICexc(5y)17.14%
ROICexgc(3y)94.66%
ROICexgc(5y)84.88%
ROCE(3y)20.57%
ROCE(5y)16.8%
ROICexgc growth 3Y10.97%
ROICexgc growth 5Y16.26%
ROICexc growth 3Y23.26%
ROICexc growth 5Y13.82%
OM growth 3Y12.14%
OM growth 5Y6.09%
PM growth 3Y15.69%
PM growth 5Y8.94%
GM growth 3Y0.74%
GM growth 5Y1.28%
F-Score8
Asset Turnover0.51
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.64 | ||
| Debt/FCF | 2.32 | ||
| Debt/EBITDA | 1.23 | ||
| Cap/Depr | 73.24% | ||
| Cap/Sales | 6.92% | ||
| Interest Coverage | 19.05 | ||
| Cash Conversion | 79.71% | ||
| Profit Quality | 109.01% | ||
| Current Ratio | 1.12 | ||
| Quick Ratio | 0.89 | ||
| Altman-Z | 4.41 |
F-Score8
WACC4.75%
ROIC/WACC4.07
Cap/Depr(3y)63.14%
Cap/Depr(5y)55.05%
Cap/Sales(3y)6.73%
Cap/Sales(5y)6.62%
Profit Quality(3y)101.15%
Profit Quality(5y)104.02%
High Growth Momentum
Growth
EPS 1Y (TTM)14.98%
EPS 3Y13.63%
EPS 5Y9.21%
EPS Q2Q%2.53%
EPS Next Y-0.14%
EPS Next 2Y4.63%
EPS Next 3Y6.15%
EPS Next 5Y7.48%
Revenue 1Y (TTM)8.91%
Revenue growth 3Y9.1%
Revenue growth 5Y2.45%
Sales Q2Q%1.39%
Revenue Next Year2.53%
Revenue Next 2Y3.82%
Revenue Next 3Y4.55%
Revenue Next 5Y4.99%
EBIT growth 1Y14.46%
EBIT growth 3Y22.35%
EBIT growth 5Y8.7%
EBIT Next Year12.61%
EBIT Next 3Y8.86%
EBIT Next 5Y8.66%
FCF growth 1Y10.42%
FCF growth 3Y9.64%
FCF growth 5Y6.62%
OCF growth 1Y8.66%
OCF growth 3Y10.38%
OCF growth 5Y7%
NOVARTIS AG-SPONSORED ADR / NVS Fundamental Analysis FAQ
What is the ChartMill fundamental rating of NOVARTIS AG-SPONSORED ADR (NVS) stock?
ChartMill assigns a fundamental rating of 7 / 10 to NVS.
What is the valuation status for NVS stock?
ChartMill assigns a valuation rating of 6 / 10 to NOVARTIS AG-SPONSORED ADR (NVS). This can be considered as Fairly Valued.
Can you provide the profitability details for NOVARTIS AG-SPONSORED ADR?
NOVARTIS AG-SPONSORED ADR (NVS) has a profitability rating of 9 / 10.
What is the financial health of NOVARTIS AG-SPONSORED ADR (NVS) stock?
The financial health rating of NOVARTIS AG-SPONSORED ADR (NVS) is 7 / 10.
Can you provide the expected EPS growth for NVS stock?
The Earnings per Share (EPS) of NOVARTIS AG-SPONSORED ADR (NVS) is expected to decline by -0.14% in the next year.